Overview

A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years

Status:
Completed

Trial end date:
2017-04-13

Target enrollment:

Participant gender:

Summary

This trial is conducted in the United States of America. The aim of this trial is to investigate safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of liraglutide in obese children aged 7 to 11 years

Phase:

Phase 1

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

Liraglutide